Lenalidomide dans les lymphomes cutanés primitifs B diffus à grandes cellules type-jambe en rechute ou réfractaires : PHRC REV-LEG

Mermin, D.; Bonnet, N.; Bouabdallah, Réda; Duval-Modeste, Anne-Bénédicte; Mortier, Laurent; Oro, S.; Ram‐Wolff, Caroline; Barète, Stéphane; Dalle, S.; Maubec, E.; Quéreux, G.; Templier, I.; Bagot, Martine; Grange, Florent; Vergier, Béatrice; Merlio, Jean-Philippe; Pham‐Ledard, Anne; Dousseau, A.; Maillard, A.; Beylot‐Barry, M.

doi:10.1016/j.annder.2016.09.172

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In case of failure or relapse, the therapeutic options are even more limited in front of the fragile field of these patients, and the aggressiveness of the lymphoma. A multi-center phase II clinical trial was conducted in GFELC to evaluate Lenalidomide for the treatment of diffuse large-cell B-cell diffuse relapsing or failing lymphoma after a first Rituximab-based therapeutic line with chemotherapy, the response was considered modest not allowing its use in the first line, and the occurrence of many side effects justified the dose reduction, other tests are necessary before the proposal of Lenalidomide for the treatment of B lymphomas Large-cell "leg-type" (Mermin ,2016;Descamps, 2011) and other studies are underway for the evaluation of lenalidomide as a second-line therapy alone or in combination with dexamethasone in the treatment of cutaneous large B-cell lymphoma leg type.…”

Section: Discussionmentioning

confidence: 99%

Case Report of Cutaneous Large B-cell leg-type Lymphoma in Young Woman

Bendari

Laajouri

Cherkaoui

et al. 2019

ESJ

View full text Add to dashboard Cite

Cutaneous diffuse B-cell lymphoma leg type is a rare entity, it represents approximately 5% of primary cutaneous lymphomas. It has a poor prognosis. We report case of t 58 years old patient with a cutaneous B cell lymphoma leg type with dual location at the upper and lower limbs and bone lysis. Histological examination of the skin biopsy showed diffuse lymphomatous proliferation dissecting collagen, made of large cells with abundant cytoplasm moderately ill-defined, ovoid nuclei and with a discreet nuclear irregularity. The immunohistochemical study revealed lymphoma cells phenotype B with a homogeneous expression of CD 20, a homogeneous expression of CD 3, CD 43 positive. Bcl 2 was positive, as the Bcl 6 and Mum 1. CD 5, CD10, MPO, CD 34, and Tdt were negative. The Ki 67 was positivein90%. The staging showed extensive osteolysis of the lower end of the humerus and the ulna. The patient received 2 courses RCHOP, with faillure of treatment, and then she received one course of RDHAP before dying. The particularity of this observation consists in the age; our patient was younger than the average, and the double localization of lymphoma in both arm and leg, with osteolysis. We discuss also the difficulties of treatment of this disease.

show abstract

Section: Discussionmentioning

confidence: 99%